Siemens Healthcare’s Mobilett Mira, the company’s first mobile digital X-ray system with a wireless detector, has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available in the United States.
Siemens Healthcare’s Mobilett Mira, the company’s first mobile digital X-ray system with a wireless detector, has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available in the United States.
The Mobilett Mira’s wireless capacity helps with examinations of patients with limited mobility, and its rotating swivel arm helps increase ease-of-use for clinical staff, the company said.
Similar to their mobile X-ray systems, the device has a rotating swivel arm so that, rather than moving the patient around, radiologists and technologists can move the swivel arm instead. Siemens officials said, though, that theirs is the first mobile X-ray device using a wireless detector, which does away with the data cable needed with other such devices.
The Mobilett Mira has 7-megapixel resolution and exposure times shorter than 1 millisecond.
The X-ray swivel arm moves vertically and rotates 90 degrees, integrating electric connection cables. In addition, the company said, the Mobilett Mira is the first mobile X-ray system that can be maintained and updated via remote monitoring. Siemens Remote Services (SRS) regularly provides the system with recommended software updates.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.